Decision support for prediction and management of Long Covid Syndrome (LCS)
Acronym
Long Covid
Description of the granted funding
We will develop tools and knowledge to support physicians in accurately managing Long COVID syndrome (LCS) which has a significant impact on sufferers as well as their surroundings. Although much is now known regarding appropriate clinical management of acute COVID-19, very little is known about clinical manifestations, risk factors and underlying mechanisms for development of the highly heterogenous LCS. In this project, we aim to understand and mechanisms of LCS by combining front-line expertise from the fields of clinical medicine, virology, metabolism and immunology. We will study the pathogenesis of LCS by conducting geographically diverse cohort and registry studies, by conducting mechanistic studies, by using novel high-throughput methods for biomarker analysis, and by conducting interventional and follow-up studies on LCS patients. We will combine results from clinical and mechanistic studies to identify molecular and physiological parameters and/or pathways to decipher the mechanisms underlying LCS. We will exploit the high-throughput omics technologies to identify the predisposing factors and biomarkers that lead to the development of LCS. We will collect data from the cohort, mechanistic, biomarker and interventional studies and use these to validate the predictive artificial intelligence algorithms and to produce information and gain understanding on the combination of factors that lead to certain clustering of patients into different groups with specific symptoms. A machine learning and AI-informed Long Covid Prediction Support (LCPS) tool will be developed for the use of clinicians to predict the LCS and its possible clinical manifestations in patients. It will also help in the choice of personalized treatments for LCS patients. Additionally, an interactive graphic user interface infographic will also be available to clinicians and patients; this will communicate novel and understandable information about LCS and recommendations for patient management.
Show moreStarting year
2022
End year
2026
Granted funding
SPINVERSE OY
406 873.44 €
Participant
IRISBIO OU (EE)
432 500 €
Participant
NEC ITALIA SPA (IT)
84 387 €
Participant
NEC LABORATORIES EUROPE GMBH (DE)
563 210 €
Participant
STEINBEIS 2I GMBH (DE)
340 000 €
Participant
CHINO SOCIETA A RESPONSABILITA LIMITATA SEMPLIFICATA (IT)
469 875 €
Participant
LIPOTYPE (DE)
480 000 €
Participant
NUROMEDIA GMBH (DE)
503 875 €
Participant
PROTOBIOS OU (EE)
221 875 €
Participant
UNIVERSITAT BASEL (CH)
Participant
ACADEMISCH ZIEKENHUIS GRONINGEN (NL)
582 957 €
Participant
UNIVERSITAT ZURICH (CH)
Participant
Amount granted
6 549 674 €
Funder
European Union
Funding instrument
HORIZON Research and Innovation Actions
Framework programme
Horizon Europe (HORIZON)
Call
Programme part
Health (11673 Infectious Diseases, including poverty-related and neglected diseases (11692 )
Topic
Personalised medicine and infectious diseases: understanding the individual host response to viruses (e.g. SARS-CoV-2) (HORIZON-HLTH-2021-DISEASE-04-07Call ID
HORIZON-HLTH-2021-DISEASE-04 Other information
Funding decision number
101057553